Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
1.08B
-
Number of holders
-
191
-
Total 13F shares, excl. options
-
61.6M
-
Shares change
-
-3.63M
-
Total reported value, excl. options
-
$390M
-
Value change
-
-$21.4M
-
Put/Call ratio
-
2.75
-
Number of buys
-
101
-
Number of sells
-
-67
-
Price
-
$6.32
Significant Holders of ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) as of Q2 2024
240 filings reported holding IBRX - ImmunityBio, Inc. - Common Stock, par value $0.0001 per share as of Q2 2024.
ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) has 191 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 61.6M shares
of 1.08B outstanding shares and own 5.71% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (13.8M shares), BlackRock Inc. (11.4M shares), STATE STREET CORP (7.86M shares), GEODE CAPITAL MANAGEMENT, LLC (3.92M shares), JANE STREET GROUP, LLC (1.72M shares), UBS ASSET MANAGEMENT AMERICAS LLC (1.58M shares), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (1.24M shares), JPMORGAN CHASE & CO (1.18M shares), NORTHERN TRUST CORP (1.14M shares), and GOLDMAN SACHS GROUP INC (1.02M shares).
This table shows the top 191 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.